Pharmacologic profile of ropinirole: A nonergoline dopamine agonist

Neurology

Volumn 49, Issue 1 SUPPL., 1997, Pages

  Tulloch, Ian F ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b New Frontiers Science Park (North)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; ROPINIROLE; TALIPEXOLE;

ARTICLE; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030835297     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.49.1_suppl_1.s58     Document Type: Article

References (35)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
2. Lang AE, Johnson K. Akathesia in idiopathic Parkinson's disease. Neurology 1987;37:477-481.
3. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias: possible treatment by increasing the daily dose of levodopa. Arch Neurol 1978;35:261-263.
4. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
5. Nutt JG. Levodopa-induced dyskinesias: review, observations, and speculations. Neurology 1990;40:340-345.
6. Rinne UK. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1983; 95(Suppl):19-26.
7. 2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
8. Fears R, Bowen WP, Brown F, et al. The novel dopaminergic agent ropinirole selectively binds to cloned dopamine D3 receptors. Can J Neurol Sci 1993;20(Suppl 4):S68.
9. Brooks DJ, Torjansk N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm Suppl 1995;45:231-238.
10. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-270.
11. De Keyser J. Subtypes and localization of dopamine receptors in human brain. Neurochem Int 1993;22:83-93.
12. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-387.
13. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
14. Cedarbaum JM, Schleifer LS. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: McGraw-Hill 1993;463-484.
15. Schachter M, Bédard P, Debono AG, et al. The role of D-1 and D-2 receptors. Nature 1980;286:157-159.
16. 3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1147-1154.
17. Greenamyre JT. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 1993;91:255-269.
18. Bédard PJ, Mancilla BG, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
19. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(Suppl 3):S6-S12.
20. Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm Suppl 1995;45:187-195.
21. Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992;10:527-540.
22. Ross EM. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: McGraw-Hill, 1993:33-48.
23. Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol 1986;17:57-62.
24. Hagen JD, Pierce PA, Peroutka SJ. Differential binding of ergot compounds to human versus rat 5-HT2 cortical receptors. Biol Signals 1994;3:223-229.
25. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological potential in Parkinson's disease. Drugs 1990;39:491-506.
26. McPherson GA. In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors. Eur J Pharmacol 1984;97:151-155.
27. Pahwa R, Koller WC. Dopamine agonists in the treatment of Parkinson's disease. Cleve Clin J Med 1995;62:212-217.
28. Ruffolo RR Jr, Cohen ML, Messick K, Horng JS. Alpha-2-adrenoceptor mediated effects of pergolide. Pharmacology 1987;35:148-154.
29. Silberbergeld EK, Hruska RE. Effects of ergot drugs on serotonergic function: behaviour and neurochemistry. Eur J Pharmacol 1979;58:1-10.
30. 3 receptors [abstract]. Br J Pharmacol 1993;110(Suppl):93P.
31. 4.4 receptors in functional studies using microphysiometry. Br J Pharmacol 1996;119(Suppl): 346P.
32. 3 affinity of the novel dopaminergic agonist ropinirole [abstract]. New Trends Clin Neuropharmacol 1994;8:298.
33. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49(Suppl 1):S26-S33.
34. Pearce RKB, Banerji T, Jenner P, Marsden CD. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets [abstract]. Br J Pharmacol 1996;118:37P.
35. Costall B, Naylor RJ, Owen RT. Investigations into the nature of the peri-oral movements induced by 2-(N,N-dipropyl) amino-5,6-dihydroxytetraline. Eur J Pharmacol 1977;45:357-367.